Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML

Blood

Volumn 87, Issue 7, 1996, Pages 2938-2946

  Dunussi Joannopoulos, Kyriaki ^a   Weinstein, Howard J ^b   Nickerson, Peter W ^b   Strom, Terry B ^b   Burakoff, Steven J ^b   Croop, James M ^b   Arceci, Robert J ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD28 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MESSENGER RNA; MYELOPEROXIDASE; OKT 8; TUMOR VACCINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; FEMALE; GENETIC TRANSDUCTION; IMMUNIZATION; INTRAVENOUS DRUG ADMINISTRATION; IRRADIATION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SPLEEN CELL; TUMOR IMMUNITY;

EID: 0029878206     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.7.2938.bloodjournal8772938     Document Type: Article

References (50)

1. Nichols J, Nimer SD: Transcription factors, translocations, and leukemia. Blood 80:2953, 1992
2. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre R, Frei E III: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331:896, 1994
3. Arceci RJ: Clinical significance of the MDRl P-glycoprotein in multidrug resistance malignancies. Blood 81:2215, 1993
4. Boon T: Toward a genetic analysis of tumor rejection antigen. Adv Cancer Res 58:177, 1992
5. Chen L, Linsley PS, Hellström KE: Costimulation of T cells for tumor immunity. Immunol Today 14:483, 1993
6. Powis SJ, Townsend ARM, Deverson EV, Bastin J, Butcher GW, Howard JC: Restoration of antigen presentation of the mutant cell line RMA-S by an MHC-linked transporter. Nature 354:528, 1991
7. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:767, 1990
8. Germain RN, Margulies DH: The biochemistry and cell biology of antigen presentation. Annu Rev Immunol 11:403, 1993
9. Berzofsky J, Brett S, Streicher HZ, Takahashi H: Antigen processing for presentation to T lymphocytes: Functional mechanisms and implications for the T-cell repertoire. Immunol Rev 105:5, 1988
10. Yewdell J, Bennink J: Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. Adv Immunol 52:125, 1992
11. Weaver CT, Unanue ER: The costimulatory function of antigen-presenting cells. Immunol Today 11:49, 1990
12. Schwarz RH: A cell culture model for T lymphocyte clonal anergy. Science 248:1349, 1990
13. Guinan EC, Gribben JG, Boussiotis VA, Freeman GJ, Nadler LM: Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood 84:3261, 1994
14. Freedman AS, Freedman G, Horowitz JC, Daley J, Nadler LM: B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol 139:3260, 1987
15. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 11:191, 1993
16. June CH, Bluestone JA, Nadler LM, Thompson CB: The B7 and CD28 receptor families. Immunol Today 15:321, 1994
17. Hellström KE, Hellström I, Chen L: Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 145:123, 1995
18. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley P: Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71:1093, 1992
19. + T cells by B7-transfected melanoma cells. Science 259:368, 1993
20. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LN, Freeman GJ, Glimcher LH: Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA 90:5687, 1993
21. Chen L, McGowan P, Ashe S, Johnston JV, Hellström I, Hellström KE: B7-1/CD80 transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 54:5420, 1994
22. Hodge JW, Abrams S, Schlom J, Kantor JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54:5552, 1994
23. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD: Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 85:2507, 1995
24. Resnitzky P, Estrov Z, Haran-Ghera N: High incidence of acute myeloid leukemia in SJL/J mice after x-irradiation and corticosteroids. Leukemia Res 9:1519, 1985
25. Markowitz D, Goff S, Bank A: A safe packaging cell line for gene transfer: Separating viral genes on two different plasmids. J Virol 62:1120, 1988
26. Miller DA, Rosman GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques 7:980, 1989
27. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294, 1979
28. Maniatis T, Fritsch EF, Sambrook J: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1982, p 545
29. Dialynas DP, Wilde DB, Marrack P, Pierres A, Wall KA, Havran W, Otten G, Loken MR, Pierres M, Kappler J, Fitch FW: Characterization of the murine antigenic determinant designated L3T4a, recognized by monoclonal antibody GK1.5: Expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 74:29, 1983
30. Ledbetter JA, Herzenberg LA: Xenogeneic monoclonal antibodies to mouse lymphoid differentiation antigens. Immunol Rev 47:63, 1979
31. Steurer W, Nickerson PW, Steele AW, Steiger J, Zheng XX, Strom TB : Ex vivo coating of islet cell allografts with murine CTLA/ Fc promotes graft tolerance. J Immunol 155:1165, 1995
32. Urban JL, Schreiber H: Tumor antigens. Annu Rev Immunol 10:617, 1992
33. Boon T, Cerottini J-C, Van den Eynde B, Van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337, 1994
34. Van Pel A, Van der Bruggen P, Coulie PG, Brichard VG, Lethe B, Van den Eynde B, Uyttenhove C, Renauld J-C, Boon T: Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229, 1995
35. Beun GDM, van de Velde CJH, Fleuren GJ: T-cell based cancer immunotherapy: Direct or redirected tumor-cell recognition? Immunol Today 15:11, 1994
36. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W: Immunity to oncogenic proteins. Immunol Rev 145:33, 1995
37. Pardoll DM: Cancer vaccines. Immunol Today 14:310, 1993
38. Townsend SE, Su FW, Atherton JM, Allison JP: Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 54:6477, 1994
39. Jenkins MK: The role of cell division in the induction of clonal anergy. Immunol Today 13:69, 1992
40. Schwartz RH: Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065, 1992
41. Rosenberg SA, Lotze MT: Cancer immunotherapy using interleukin-2 and interieukin-2-activated lymphocytes. Annu Rev Immunol 4:681, 1986
42. Iwahashi M, Tanimura H, Yamaue H, Tsunoda T, Tani M, Tamai M, Noguchi K, Hotta T: Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients. Int J Cancer 51:67, 1992
43. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC: Alterations in signal transduction molecules in T-lymphocytes from tumor-bearing mice. Science 258:1795, 1992
44. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komslies KL: Alterations in NF kappa B/ Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54:2969, 1994
45. Ochoa AC, Longo DL: Alteration of signal transduction in T cells from cancer patients, in De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, p 43
46. Liu Y, Janeway CA Jr: Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci USA 89:3845, 1992
47. + T cells by delivery of the B7 costimulatory signal on bystander antigen-presenting cells (trans-costimulation). Eur J Immunol 24:859, 1994
48. Döhring C, Angman L, Spagnoli G, Lanzavecchia A: T-helper and accessory-cell-independent cytotoxic responses to human tumor cells transfected with a B7 retroviral vector. Int J Cancer 57:754, 1994
49. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J Immunol 153:421, 1994
50. Nanda NK, Sercatz EE: Induction of anti-self-immunity to cure cancer. Cell 82:13, 1995